JP2019524657A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524657A5
JP2019524657A5 JP2018566390A JP2018566390A JP2019524657A5 JP 2019524657 A5 JP2019524657 A5 JP 2019524657A5 JP 2018566390 A JP2018566390 A JP 2018566390A JP 2018566390 A JP2018566390 A JP 2018566390A JP 2019524657 A5 JP2019524657 A5 JP 2019524657A5
Authority
JP
Japan
Prior art keywords
acid
otic pharmaceutical
ear
pharmaceutical formulation
triglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018566390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524657A (ja
JP7033789B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/040055 external-priority patent/WO2018005830A1/en
Publication of JP2019524657A publication Critical patent/JP2019524657A/ja
Publication of JP2019524657A5 publication Critical patent/JP2019524657A5/ja
Priority to JP2022014411A priority Critical patent/JP2022070876A/ja
Application granted granted Critical
Publication of JP7033789B2 publication Critical patent/JP7033789B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018566390A 2016-06-29 2017-06-29 トリグリセリド耳用製剤とその使用 Expired - Fee Related JP7033789B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022014411A JP2022070876A (ja) 2016-06-29 2022-02-01 トリグリセリド耳用製剤とその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356300P 2016-06-29 2016-06-29
US62/356,300 2016-06-29
PCT/US2017/040055 WO2018005830A1 (en) 2016-06-29 2017-06-29 Triglyceride otic formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022014411A Division JP2022070876A (ja) 2016-06-29 2022-02-01 トリグリセリド耳用製剤とその使用

Publications (3)

Publication Number Publication Date
JP2019524657A JP2019524657A (ja) 2019-09-05
JP2019524657A5 true JP2019524657A5 (https=) 2020-08-13
JP7033789B2 JP7033789B2 (ja) 2022-03-11

Family

ID=60787747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566390A Expired - Fee Related JP7033789B2 (ja) 2016-06-29 2017-06-29 トリグリセリド耳用製剤とその使用
JP2022014411A Pending JP2022070876A (ja) 2016-06-29 2022-02-01 トリグリセリド耳用製剤とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022014411A Pending JP2022070876A (ja) 2016-06-29 2022-02-01 トリグリセリド耳用製剤とその使用

Country Status (9)

Country Link
US (2) US10821185B2 (https=)
EP (1) EP3478269A4 (https=)
JP (2) JP7033789B2 (https=)
KR (1) KR20190024983A (https=)
CN (1) CN109689027A (https=)
AU (1) AU2017290256A1 (https=)
CA (1) CA3029281A1 (https=)
IL (1) IL263828A (https=)
WO (1) WO2018005830A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
HRP20241559T1 (hr) * 2016-05-18 2025-02-14 Sound Pharmaceuticals Incorporated Ebselen za uporabu u liječenju menierove bolesti
CN110753702B (zh) * 2017-03-15 2022-09-20 清华大学 抗trkb抗体
US20200345542A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
US11918653B2 (en) * 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
WO2019140012A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
CN112020359A (zh) 2018-02-09 2020-12-01 分贝治疗公司 含有抗铂化学保护剂的高渗药物组合物
CN112805238A (zh) * 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠和其调配物
US12121501B2 (en) 2018-09-12 2024-10-22 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
US20200214976A1 (en) * 2019-01-09 2020-07-09 Spiral Therapeutics, Inc. Self-gelling solutions for administration of therapeutics to the inner ear
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
CN114040782A (zh) * 2019-04-30 2022-02-11 威斯康星州医药大学股份有限公司 跨鼓膜递送平台及其用途
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
US12246024B2 (en) * 2019-12-13 2025-03-11 Free State Pharma Inc Compositions and methods for controlling cerumen production
WO2021127275A1 (en) * 2019-12-17 2021-06-24 Otonony, Inc. Gsk-3 modulator otic formulations
EP4114975B1 (en) * 2020-03-06 2026-04-29 Regeneron Pharmaceuticals, Inc. Fascin-2 (fscn2) variant and use thereof
WO2022047234A1 (en) * 2020-08-28 2022-03-03 President And Fellows Of Harvard College Drug combination kits and methods of drug delivery
CA3198930A1 (en) 2020-11-19 2022-05-27 Acousia Therapeutics Gmbh Non-aqueous gel composition
WO2022126124A1 (en) * 2020-12-10 2022-06-16 Joseph Passman Radiopaque marking compositions and delivery thereof
WO2022140636A1 (en) * 2020-12-22 2022-06-30 Otonomy, Inc. Gacyclidine otic formulations and uses thereof
CN112980878B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
JP7699789B2 (ja) * 2021-04-30 2025-06-30 ソウル ナショナル ユニバーシティ ホスピタル 感音性難聴の原因特異的治療効果を予測する方法及びそのために使用される診断キット
CN113416608B (zh) * 2021-06-29 2023-04-28 中国热带农业科学院热带作物品种资源研究所 一种抑制单增李斯特菌的益智精油的提取方法及益智精油
EP4431095A4 (en) * 2021-11-08 2025-03-26 Mitsubishi Gas Chemical Company, Inc. Ergothioneine-containing composition for suppressing or preventing hearing loss in the inner ear
CN115068611B (zh) * 2022-06-24 2023-04-18 天津市农业科学院 ssc-miR-374b-3p在制备抗PDCoV增殖药物中的应用
WO2024015363A1 (en) * 2022-07-11 2024-01-18 The Johns Hopkins Univeristy Compositions and formulation methods for sustained local release of antifibrotics
CN115644879B (zh) * 2022-11-10 2024-08-27 合肥曦合超导科技有限公司 一种实现超导磁屏蔽的脑磁图检测设备
CN116751866B (zh) * 2023-08-09 2023-10-31 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 中耳胆脂瘤的标志物及其应用
TR2023015006A2 (tr) * 2023-11-14 2023-12-21 T C Ankara Ueniversitesi Rektoerluegue Rbd nanoparti̇kül i̇le yüklenmi̇ş çözünen mi̇kroi̇ğneleri̇n geli̇şti̇ri̇lmesi̇ ve kullanimi
CN117398404B (zh) * 2023-12-15 2024-03-08 北京大学口腔医学院 一种miRNA-141-5p在制备用于治疗牙周炎症性疾病药物中的应用

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4474572A (en) 1981-09-29 1984-10-02 Syntex (U.S.A.) Inc. Implanting device and implant magazine
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4758435A (en) 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
EP0504257A4 (en) 1989-11-29 1993-03-03 Brigham And Women's Hospital (ala il-8) 77 as a leukocyte adhesion inhibitor
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5122377A (en) * 1990-11-19 1992-06-16 A.H. Robins, Company, Incorporated Oral delivery system for veterinary drugs
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2113094T3 (es) 1993-03-09 1998-04-16 Epic Therapeutics Inc Las microparticulas macromoleculares y metodos de obtencion.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
JPH10503179A (ja) 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
GB9505032D0 (en) 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
AU1739097A (en) 1996-02-23 1997-09-10 Albert Einstein College Of Medicine Of Yeshiva University Enzyme detection/assay method and substrates
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
SI1165564T1 (sl) 1999-04-08 2009-08-31 Ind Res Ltd Postopek priprave inhibitorjev metabolizma nukleozidov
DK1180159T3 (da) 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
DK1194425T3 (da) 1999-06-23 2005-11-21 Aventis Pharma Gmbh Substituerede benzimidazoler
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7151191B2 (en) 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
CA2412494C (en) 2000-06-22 2012-10-23 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7109331B2 (en) 2000-08-29 2006-09-19 Industrial Research Limited 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
EP1331945A2 (en) * 2000-09-25 2003-08-06 Bayer Healthcare, LLC Otic microbial combinations for treatment of animals with ruptured tympanic membrane
JP2004532797A (ja) 2000-10-12 2004-10-28 スミスクライン・ビーチャム・コーポレイション NF−κB阻害剤
EP1324759A4 (en) 2000-10-12 2004-05-12 Smithkline Beecham Corp NF - G (K) B INHIBITORS
ES2305125T3 (es) 2000-10-26 2008-11-01 Amgen Inc. Agentes anti-inflamatorios.
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag 4−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
CA2433840C (en) 2001-01-04 2010-05-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
PL364111A1 (en) 2001-02-01 2004-12-13 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk)
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
ATE363473T1 (de) 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
EP1444207A2 (en) 2001-09-19 2004-08-11 Pharmacia Corporation Substituted pyrazolyl-compounds for the treatment of inflammation
EP1448545B1 (en) 2001-10-04 2008-11-19 Smithkline Beecham Corporation Nf-kb inhibitors
JP2005528331A (ja) 2001-11-21 2005-09-22 イェシバ・ユニバーシティ Sir2産物および活性
JP2005518371A (ja) 2001-12-10 2005-06-23 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療に於けるこれらの使用
HUP0500200A2 (hu) 2002-01-17 2005-07-28 Neurogen Corporation Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
JP2003277383A (ja) 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
MXPA04011472A (es) 2002-05-22 2005-02-14 Amgen Inc Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR041191A1 (es) 2002-08-08 2005-05-04 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
DE602004025460D1 (de) 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
US20040247575A1 (en) 2003-06-03 2004-12-09 Caplice Noel M. Smooth muscle progenitor cells
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GEP20094676B (en) 2003-07-24 2009-05-10 Euro Celtique Sa Piperidine compounds and pharmaceutical compositions containing them
EP1670794A2 (en) 2003-09-30 2006-06-21 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AP2006003670A0 (en) 2003-12-23 2006-06-30 Rinat Neuroscience Corp Agonist anti-TRKC antibodies and methods using same
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP2007537266A (ja) 2004-05-12 2007-12-20 アベンティス・ファーマスーティカルズ・インコーポレイテツド IκBキナーゼ阻害剤として実質的に純粋な2−{[2−(2−メチルアミノ−ピリミジン−4−イル)−1H−インドール−5−カルボニル]−アミノ}−3−(フェニルピリジン−2−イル−アミノ)−プロピオン酸
US8870826B2 (en) 2004-05-24 2014-10-28 Auris Medical Llc Combined otic aspirator and medication dispenser
US8498681B2 (en) 2004-10-05 2013-07-30 Tomophase Corporation Cross-sectional mapping of spectral absorbance features
US20060105967A1 (en) 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Flavone derivatives as TNFalpha inhibitors or antagonists
CN101090707A (zh) * 2004-12-09 2007-12-19 拜耳医药保健股份公司 用于在耳内卫生给药的药物
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
JP5002462B2 (ja) 2004-12-09 2012-08-15 バイエル・アニマル・ヘルス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 酸によるグルココルチコイドエステルの安定化
WO2006076318A1 (en) 2005-01-12 2006-07-20 Aventis Pharmaceuticals Inc. Monopotassium salt of an ikb kinase inhibitor
EP1850840A2 (en) 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
EP1836203A2 (en) 2005-01-14 2007-09-26 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
CN101232885A (zh) 2005-01-25 2008-07-30 神经能质公司 经取代的哒嗪基喹啉-4-基胺和嘧啶基喹啉-4-基胺类似物
US20060221197A1 (en) 2005-03-30 2006-10-05 Jung Edward K Image transformation estimator of an imaging device
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP2008531726A (ja) * 2005-03-04 2008-08-14 ニューロシステック コーポレイション 改良されたガシクリジン製剤
ES2331153T3 (es) 2005-03-10 2009-12-22 Pfizer Inc. Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
US7312233B2 (en) 2005-03-14 2007-12-25 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA200701745A1 (ru) 2005-03-17 2008-06-30 Пфайзер, Инк. Циклопропанкарбоксамидные производные
EP1893583B1 (en) 2005-05-31 2012-04-04 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US20070219272A1 (en) 2006-02-06 2007-09-20 Johan Stjernschantz Novel method and compositions for treatment of tinnitus
US7760617B2 (en) 2006-03-24 2010-07-20 Lg Electronics Inc. Method and structure of configuring preamble to support transmission of data symbol in a wireless communication system
US7744746B2 (en) 2006-03-31 2010-06-29 Exxonmobil Research And Engineering Company FCC catalyst stripper configuration
CA2661576A1 (en) * 2006-09-26 2008-04-03 Taro Pharmaceuticals North America, Inc. Stabilizing compositions for antibiotics and methods of use
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2008078179A1 (en) 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
US8188131B2 (en) 2008-02-07 2012-05-29 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
US9200080B2 (en) 2010-09-03 2015-12-01 Horacio Uri Saragovi Agonistic antibodies to TrkC receptors and uses thereof
WO2012047706A2 (en) 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
EP2667881A4 (en) 2011-01-24 2015-04-22 Univ Leland Stanford Junior METHOD FOR IN VITRO GENERATION OF INTERNAL CELLS
EP2765992A4 (en) * 2011-10-10 2015-04-08 Otic Pharma Ltd FOAM FORMULATIONS
DE202012100195U1 (de) 2012-01-19 2012-03-01 Nordmark Arzneimittel Gmbh & Co. Kg Neue Verwendung einer pharmazeutischen Zusammensetzung, enthaltend Ancrod
WO2013124416A1 (en) 2012-02-23 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
WO2013173803A2 (en) * 2012-05-17 2013-11-21 Michael Spector Formulations of amoxicillin and clavulanate potassium and methods for using same
EP2854829A1 (en) 2012-05-30 2015-04-08 Sensorion Methods for treating vestibulotoxicity
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
EP2853533A1 (de) 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
CN107072940A (zh) * 2014-07-29 2017-08-18 奥德纳米有限公司 用于治疗耵聍分泌过多的耳用制剂
FR3024361B1 (fr) 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
EP2982382A1 (en) 2014-08-04 2016-02-10 Sensorion Compounds for preventing ototoxicity
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
DE202015100655U1 (de) 2015-02-03 2016-02-04 Bio.Lo.Ga. S.R.L. Pharmazeutische Zusammensetzung zur topischen Anwendung im Gehörgang
WO2016128438A1 (en) 2015-02-11 2016-08-18 Support-Venture Gmbh Method of preventing or treating hearing loss
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch

Similar Documents

Publication Publication Date Title
JP2019524657A5 (https=)
RU2469726C2 (ru) Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
RU2499592C2 (ru) Фармацевтическая композиция для лечения ушных заболеваний
JP7569336B2 (ja) マイクロエマルション組成物
US8784870B2 (en) Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CA2731766C (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
ES2538479T3 (es) Composiciones oftálmicas y óticas de polímeros y oligómeros facialmente anfifílicos y sus usos
AU2019275578B2 (en) Sterilization of ciprofloxacin composition
ES2635197T3 (es) Composición farmacéutica que tiene biodisponibilidad deseable
JP2011529854A5 (https=)
AU2009330458B2 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
TWI650122B (zh) 用於預防及/或治療乾眼症之組成物、方法及/或裝置
JP2006509791A (ja) 耳に薬理的作用物質を適用するための方法及び組成物
JP2018030871A (ja) 非刺激性の眼科用ポビドンヨード組成物
CN118453493A (zh) D2o稳定化的药物制剂
US20230277452A1 (en) Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation
CN115869389A (zh) 生长因子耳用制剂
US20220233522A1 (en) Ciprofloxacin otic composition and kits and method for using same
CN105682742A (zh) 小儿耳部病症的治疗
US20210393511A1 (en) Otic gel formulations for treating otitis externa
JP2011021002A (ja) 眼科用組成物
JP2009196934A (ja) ニューキノロン系抗菌薬及び乳剤性基剤を含む医薬組成物
CN108472313A (zh) 用于治疗耳炎的组合物和方法
US20170049782A1 (en) Active ingredient (i) containing composition and method for preparing same
RU2787998C1 (ru) Микроэмульсионные композиции